NOTCH1 and B-cell chronic lymphocytic leukemia: Interestingly, results from the CLL8 trial comparing fludarabine, cyclophosphamide, rituximab (FCR) versus fludarabine, and cyclophosphamide (FC) as first line therapy in CLL patients demonstrated that NOTCH1 mutated patients may not benefit from the addition of the type 1 anti-CD20 mAb rituximab.